Novel Targeted Combinations in CNS Lymphoma

Grzegorz Nowakowski, MD, of the Mayo Clinic, moderated a discussion on central nervous system (CNS) lymphoma with an expert panel featuring Christian Grommes, MD, of the Memorial Sloan Kettering Cancer Center; Katherine Peters, MD, PhD, of the Preston Robert Tisch Brain Tumor Center; and Avyakta Kallam, MD, of the City of Hope Comprehensive Cancer Center.

In this segment, the experts discussed novel targeted combinations in CNS lymphoma, including Bruton tyrosine kinase (BTK) inhibitors in combination with interleukin-1 receptor-associated kinase (IRAK) inhibitors and BTK inhibitors in combination with chemotherapy.